Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary
August 6, 2024
Earnings Call Speaker Segments
Melissa Jarel
executiveThanks, operator, and good afternoon to all of you. We appreciate you being with us on this Heron Therapeutics call today as we go over the company's financial results for the quarter that closed on June 30, 2024. Joining me from Heron are Craig Collard, our Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; and Kevin Warner, Senior Vice President, Medical Affairs Strategy & Engagement. If you're on the conference call, slides are available through webcast, and you can also find them on the Investor Relations page of our website once today's call wraps up. At the outset, please note that forward-looking statements will be made by the company on this call; anything that is not a historical fact should be treated as cautionary and forward-looking. This includes comments about projections, expectations, plans, beliefs and future performance, all of which qualify as forward-looking statements under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Statements of this kind are based on judgment and analysis as of today's conference call date and carry numerous significant risks and uncertainties that may cause actual results to differ materially from what those forward-looking statements describe. Details about the hazards and unknowns connected to the predictive remarks given during this call and webcast can be found in the safe harbor language included in the press release issued today, as well as in the periodic documents Heron files with the SEC. Unless legally mandated, Heron takes on no duty to revise these forward-looking statements so they mirror later occurrences or real results, and has no plan to do so. Having said that, I will now hand things over to Craig Collard, Heron's Chief Executive Officer.
Craig Collard
executiveMelissa, thank you. Good morning to all, and glad you could join us for Heron Therapeutics' call covering results from the second quarter of 2024. We're happy today to bring you up to speed on what we accomplished most recently in Q2, covering a tightened outlook on our finances along with a look at how we performed financially, a review of how our products did, movement of the Vial Access Needle, or VAN, toward the PDUFA date of September 23, the release of the long awaited NOPAIN Act, which covers ZYNRELEF, and finally, news about construction and instruction of our colleagues at CrossLink. Let's turn now to how we did financially. This slide, I think, shows what our fresh leadership group has accomplished for this company by setting the first half of 2024 against the first half of 2023. Remember that our management group only became fully assembled in August of 2023. From the time we came aboard, we've built the right kind of financial stewardship, which let us cut spending sharply while continuing to grow revenue at the top line. The slide makes clear that revenue rose 15%, gross margin went from 40% up to 73%, and operating expenses fell by more than $36 million, measuring the first 6 months of 2024 against the identical stretch in 2023. Let's move on to how the products performed. Our oncology business keeps exceeding what we projected, with CINVANTI net revenues climbing $24.9 million during the quarter and SUSTOL net revenues reaching $4.3 million during the quarter; within a highly competitive setting for oncology, we've held onto the market share we already had, and we expect these items to keep displaying comparable steadiness across 2024. Net revenues for the acute care segment overall came to $6.8 million in the quarter, a record for that business. ZYNRELEF net revenues during the quarter totaled $5.8 million. APONVIE net revenues for the quarter came in at $1 million, twice what we saw in this year's Q1. Though we're happy with where things are heading, we recognize we're still in transition with our newly broadened ZYNRELEF label, adding the CrossLink team, and the advanced submission plus launch coming later in the year, all of which will significantly affect not just ZYNRELEF as we get deeper into the year and head into 2025. It will also affect APONVIE, since these steps will open up additional selling time for our sales force and let us build stronger pull-through from the accounts we've won. When we consider how APONVIE is doing, we should remember that APONVIE is the sort of product where wins at the system level can happen. To put it plainly, once we succeed at the P&T and formulary level, protocols may be established so that APONVIE gets used across our hospital system for a particular patient or surgery type. This slide shows that we keep adding P&T wins along with new customers placing orders. With every new account we win, the aim is to get a protocol in place. First, you get the product placed inside a hospital system, and after that you work on growing its use there. On Slide 10, there's a dashboard showing how we project our APONVIE business; we've set up a way of dividing accounts into groups according to how many surgical procedures happen at each one. From a commercial standpoint, this helps us direct our sales force more effectively and assess how each account performs inside its tier. In our view, the biggest opening lies with surgical patients arriving in the operating room who carry a moderate or high risk of developing postoperative nausea and vomiting. That risk assessment is already being done before surgery throughout the country, relying on a validated set of questions that classifies these patients dependably. According to the medical literature, roughly 1 in 2 patients, or 50%, show up as moderate to high-risk. Our internal sales goal is to reach market penetration of 40% among that 50% of high-risk patients — put another way, 20% of the total surgical opportunity through business we convert. Today's opportunity amounts to a $30 million potential stemming from the 320 accounts that are currently under contract. Our confidence in APONVIE rests on how easy it is to use, its superior onset of action through intravenous administration, the lack of infusion reactions, and the lack of particular central nervous system and cardiovascular side effects associated with other agents. We see a chance to convert business by using APONVIE at times when other approaches to preventing PONV still show a failure rate of approximately 30% in this high-risk population. Naturally, Slide 10 reflects only the business Heron has right now. Roughly 75 million surgical procedures take place in the U.S. each year. Although reaching 20% penetration of the whole market might not be attainable, Heron does believe that as we convert additional accounts, APONVIE is <<inaudible>>. Turning to ZYNRELEF, it's worth noting the progress and the number of product improvements headed our way in 2024. January began with a highly anticipated label expansion, which now permits ZYNRELEF to be used far more widely across the various surgeries performed at a given hospital or ASC. The second is the launch of the VAN, which, assuming approval in September, will go live in Q4. Then there's ZYNRELEF's inclusion in the eagerly awaited NOPAIN Act, which will keep allowing ZYNRELEF to be reimbursed outside of the surgical bundle, and finally the CrossLink partnership, which keeps moving forward. It's somewhat simpler to grasp the VAN's impact once you look at both devices side by side. Our existing setup, using the VVS, or Vented Vial Spike, shown on the left-hand side of the slide, is considerably harder to use than the VAN, or Vial Access Needle, on the right-hand side of the slide. The 2 primary benefits the VAN brings are sterility and the speed at which product is withdrawn from the vial. Preparing ZYNRELEF has been its Achilles' heel ever since launch. We think that getting the VAN out later this year, together with the broader label and having a CrossLink presence in the OR study, is going to give ZYNRELEF a tremendous lift in the years ahead. Now turning to the NOPAIN Act. CMS just put out its Outpatient Prospective Payment System, OPPS, and Ambulatory Surgical Center, ASC, proposed rule for calendar year 2025. Those rules contained the non-opioid policy for pain relief, which the NOPAIN Act backed. As we anticipated, ZYNRELEF was the key product in the rule; this is going to help Heron and our patients on multiple levels. Having ZYNRELEF in the rule will boost awareness, take away financial barriers, drive adoption and endorses its use. The acronym NOPAIN stands for Non-Opioids Prevent Addiction in the Nation, which is by itself a strong endorsement. What the Act aimed to do was make sure patients can access non-opioid alternatives and that providers aren't financially incentivized to use opioids instead. To qualify for inclusion, the medications need to have an indication for postoperative pain, not act upon the body's opioid receptors and have proven efficacy in the ability to replace, reduce, or avoid intraoperative and postoperative opioid use. CMS agreed that ZYNRELEF's clinical attributes meet these requirements.
Craig Collard
executiveFor calendar year 2025, CMS put forward including ZYNRELEF in the policy, taking effect April 1, 2025, and that guarantees ZYNRELEF qualifies for separate payment outside the surgical bundle. Given what CMS did, plus the backing for non-opioid therapies, we think far more commercial payers may well do the same. On the whole, the proposed rule left us very encouraged, and in the end it will help drive greater adoption of ZYNRELEF. Training alongside the CrossLink team began with the executive team in late February, and everyone else started in early March. Right now, we have 561 CrossLink reps, made up of joint trauma and spine, who are fully trained and out in the field selling ZYNRELEF across 28 states. Clearly, none of these new sales folks were in the field during Q2, and although our progress pleases us, this process includes a learning curve. Take one example: after a new CrossLink group finishes training, our sales teams start interacting to figure out physician and account targeting, IDN formulary strategy, product messaging for a particular account, and in the end a planned attack inside a territory. We still intend to keep widening our reach nationwide, with more than 650 reps fully trained and integrated ahead of the VAN launch in Q4 this year; the CrossLink team keeps impressing us, along with the relationships they hold with the orthopedic surgical community, and we recognized back then that this would have a substantial effect on ZYNRELEF revenues. During Q2 by itself, we had more than 350 new surgeon introductions, which produced 98 new prescribing physicians, amounting to 33 new ordering accounts; clearly this hasn't yet made a major difference to revenues, but we think the effect will be substantial over time. A lot of these new introductions involve top prescribing physicians who have deep relationships with CrossLink. Like any new drug, physicians need some time before they feel comfortable with something new or different, particularly given how uniquely ZYNRELEF is delivered and applied. Getting the CrossLink team trained and into the field has left us extremely pleased. As we head into 2025 and beyond, we believe this partnership will completely change the direction of ZYNRELEF. I'll now hand the call to Ira Duarte, our CFO, to cover our financials and update our financial guidance. Go ahead, Ira.
Ira Duarte
executiveAppreciate that, Craig. Craig already went through how our products performed and what our operating results look like, so I'll just layer in a few extra items regarding what we saw in Q2 2024. For the 3 months that closed on June 30, 2024, product gross profit came in at $25.5 million, or 71%, up from 37% during the equivalent stretch of 2023. The main driver here is that this quarter didn't carry the big inventory write-offs that hit us in that comparable quarter of 2023. Looking at year-to-date figures, product gross profit reached $51.7 million, or 73%, climbing from 40% across the same period in 2023. SG&A expenses for the 3 and 6 months that ended June 30, 2024, came to $27.5 million and $53.9 million, respectively, versus $40.8 million and $77.8 million, respectively, during the matching period in 2023. That drop stems largely from lower personnel and related costs tied to reductions in force carried out in prior years, plus better cost efficiencies throughout every department. Research and development expenses landed at $4.4 million and $9 million for the 3 and 6 months ended June 30, 2024, against $13.2 million and $22 million in the comparable period of 2023. This decline mostly reflects lower personnel and related costs from reductions in force put in place in earlier years, along with reduced development activities. During the quarter, inventory write-offs of $1.6 million were incurred, though unlike last year's write-off, inventory management was not the cause. Beyond that, we also reported an asset payment write-off of $1.3 million tied to projects that are no longer part of the company's forward-looking strategy. As the Slide shows, stripping out depreciation and amortization, stock-based compensation, the inventory write-off and the asset impairment write-off would leave our adjusted operating results at positive $1.7 million in operating income, which marks a substantial turnaround in how our business is financially managed. As the 10-Q notes, the condensed consolidated statement of operations and comprehensive loss as of June 30, 2023, reflects reclassification of certain expenses out of research and development and into general and administrative expenses so they align with functional expenses incurred; total operating expenses were unchanged by this. Net loss came to $9.2 million for the 3 months ended June 30, 2024, and $12.4 million for the 6 months ended June 30, 2024, versus $42.1 million and $74.8 million, respectively, in the comparable period of 2023. Cash and short-term investments stood at $62.7 million as of June 30, 2024. These results show just how much tremendous progress we've made over the last 12 months in cutting expenses and building efficiencies within the company. That's why we are narrowing the guidance range we previously gave of $180 million to $160 million for adjusted operating expenses down to a range of $107 million to $111 million. Adjusted operating expenses exclude stock-based compensation, depreciation and amortization, and going forward, we will also exclude impairment of long-lived assets and inventory write-offs. Additionally, we're tightening the guidance range we provided earlier for adjusted EBITDA, which was a loss of $22 million to income of $3 million, down to a range spanning a $10 million loss to $3 million in income. Stock-based compensation, depreciation, and amortization are all left out of adjusted EBITDA, and starting now, impairment of long-lived assets along with inventory write-offs will be excluded as well; at this point, we'd like to begin the question-and-answer portion of the call.
Brandon Folkes
analystNice work on all the positive momentum this quarter. First off, regarding ZYNRELEF, I was wondering if you could share anything about where you're seeing the strongest adoption — whether in joint trauma or spine — through the CrossLink partnership?
Craig Collard
executiveMy apologies, Brandon, would you mind repeating that?
Brandon Folkes
analystIs there any detail you can share about which areas—joint trauma or spine—are gaining the most traction through the CrossLink collaboration? Has anything unexpected come up there?
Craig Collard
executiveSure. At this stage, as I mentioned earlier, we've been bringing the CrossLink group up to pace. During Q2, approximately 200 people had, so to speak, completed training. Because of that, we haven't yet been in a position to dig deeply into the numbers and identify where our biggest effect is felt. Clearly, orthopedic surgeons account for the bulk of our time. That said, right now I simply can't break the data down to that degree of granularity to pinpoint a specific area or show a greater effect in one spot versus another.
Brandon Folkes
analystAll right. And maybe, clearly, you did an outstanding job this quarter when it came to rep training with CrossLink. Could you expand on when you think that revenue trajectory will shift for ZYNRELEF? Is it necessary to retrain the CrossLink team once the VAN reaches the market, or just how comprehensive does that training have to be?
Craig Collard
executiveYeah. So along the way, we've been discussing the VAN, and they're aware that it's definitely on the way. And I believe it's clearly expected; we do expect that everyone will be fully trained before the VAN launches. And once more, so we believe that will definitely make a difference, but there will definitely be a briefing after the approval about precisely what gets approved and then, you know, the launch timing and all of that. So we'll walk through it with them again, but they are being briefed about, you know, what's happening and what lies ahead.
Brandon Folkes
analystExcellent. Many thanks. Wonderful to hear about that advancement. Perhaps one final item from my side. Regarding the gross margin figure, clearly, huge improvement versus the same period last year. What's the right way to think about the current quarter relative to what lies ahead? And that's all from me. I appreciate it.
Craig Collard
executiveRight now, once more, as we've consistently stated, our expectation is that we'll land in the neighborhood of the low to mid-70s; we expect that to persist. Once again, depending on product mix and similar factors, there could be slight fluctuation, yet that's the band we should remain in.
Serge Belanger
analystFirst, Craig, regarding ZYNRELEF, could you paint a picture for us of where reimbursement and coverage currently stand in the Medicare and Commercial segments, and how do you expect that to shift once you move to NOPAIN next year? Then, second, on CINVANTI, I believe a bench trial took place last month, or in June, late June, in the patent infringement lawsuit. Could you provide an update on when a decision is expected and what the possible outcomes might be, and things along those lines? Thank you.
Craig Collard
executiveYes, absolutely. In fact, Serge, Kevin Warner is also on the call. I'll have him take the first part of that, and then I'll speak to the CINVANTI portion.
Kevin Warner
executiveAppreciate that, Serge. When it comes to reimbursement and what that landscape looks like, you can't treat NOPAIN the same way as a product holding pass-through status. As things stand at this moment, ZYNRELEF needs pass-through status in order to get reimbursed. That covers every one of our patients in hospital outpatient procedure departments, plus all of our ASC patients who are under Medicare. Turning to commercial payers, somewhere in the range of 30% to 50% of them are on board, and that figure shifts depending on which state and which region you're looking at. That being said, NOPAIN flips that paradigm around, given the way NOPAIN is worded, and because historically a large number of commercial payers tend not to come on and consistently abide by these pass-through drug stipulations. But with NOPAIN, and given that it carries clinical attributes and reasoning behind using nonopioids and reducing the impact opioids have in our nation, there's, I'd say, a stronger push for them to get in line with the statute, along with the possibility that it could be extended in perpetuity and keep delivering that reimbursement. So the commercial payers, and a few others, are going to want to land on the right side of the fence when it comes to this paradigm — they grasp the cost efficacies, the clinical efficacies, and the overall economic model. So we anticipate seeing additional commercial payers come on board with NOPAIN, and from the CMS perspective, NOPAIN really doesn't alter the current reimbursement.
Craig Collard
executiveAlright. Like you mentioned, the trial wrapped up in June. And once more, as we've consistently stated, we're quite at ease with what took place during that trial. Our positioning feels very solid to us. And again, this shift essentially boils down to — infringement has, in a sense, been established in this case, and everything truly hinges on obviousness. And once more, that's precisely where we believe the invention we came up with here was one of a kind. Merck carried this product for years as a product set yet couldn't obtain it in this form; so that genuinely is what it comes down to regarding burden of proof there. And again, we believe <<inaudible>> failed to satisfy that, and we feel quite at ease with where we stand.
Serge Belanger
analystAnd do you anticipate a <<inaudible>> 30-month expiration arriving in December — is that the point when you believe a court decision will come?
Craig Collard
executiveYes. What's left to complete is the closing orders, and after that we anticipate a decision coming in Q4 of this year.
Clara Dong
analystHello, I'm Clara, filling in for Kelly. We appreciate you answering our question. Would you remind us of the number of CrossLink representatives who were out in the field selling product in Q2, and how that figure will shift during the second half of 2024? Also, given what we've seen in the field up to now, I'd like to know whether any feedback has come in, and whether you believe anything could be incorporated into training for the reps still to come, or perhaps for reps already onboard, that would assist them with selling the product. Thank you.
Craig Collard
executive<<inaudible>> CrossLink, starting with North Carolina, then top line in Georgia, and from there we expanded. By Q2, I believe we had a couple of hundred reps, and we had just moved into maybe 12 states. As things stand today, we're at 561 reps across 28 states, and that keeps increasing; once more, our expectation is that we'll exceed 650 when we launch with a VAN. So when you consider inflection and how all of this truly comes together — many developments have occurred this year, clearly, including the NOPAIN Act, our label expansion, and getting the CrossLink team trained. Yet there's one more element here as well: the integration with our sales force, overseeing that, collaborating, targeting accounts, and so on, and that simply requires time. Thus I've maintained throughout that we see the VAN launch and the transition out of Q4 into Q1 of '25 as the point when a majority of inflection starts showing up in the following year; and I suppose some of this just needs time for everything to get fully up to speed and integrated.
Kevin Warner
executiveCarl, thanks for the kind words about our progress. Let's say a generic version of Exparel shows up at some point — how would that shift things, if it does at all, for ZYNRELEF? Thanks, and I've also got a follow-up coming. Hey Carl, this is Kevin Warner. I'll take that one, and I appreciate it. So the way I'd frame it is: if a generic arrives, and if it does, what would the effect be on ZYNRELEF? Getting to market faces several hurdles, and the branded maker right now holds a number of patents it has confidence in. It's possible we haven't yet seen a sample, or it isn't known whether one of the generic makers could achieve scale, so to speak, since they've consistently described that as quite difficult. That said, should a generic product actually reach the market, the next big hurdle would be the potential absence of a financial upside. Most generics, historically, enter the market as you'd expect — priced below the branded product so the healthcare system gets a financial break. Yet in the economic environment we have today, particularly given the NOPAIN Act and wider commercial reimbursement, those benefits would essentially be neutralized, so to speak; so broadly, even for Exparel to that degree, with the reimbursement package coming from NOPAIN, follow-on commercials could win out by using a genericized product. As for the prospect of additional non-opioid analgesics broadly reaching the market, what I see is synergy rather than conflict, since medical practice is shifting toward opioid-sparing therapies, and novel mechanisms are required to deliver the most effective multimodal therapy. So be it generic liposome, bupivacaine used as a regional block, or an oral NAV1.8 inhibitor such as Vertex Suzetrigine, I see chances for ZYNRELEF, as the best-in-class local installation product, to be paired with those other modalities as we all pursue one shared aim, correct? Which is to reduce or remove the need for opioids. At a fundamental level, though, and just briefly, if we consider liposomal bupivacaine as a competitor or not, you need to examine the key distinctions that define a drug, right, so to speak — the active ingredients, the dose, the route, the frequency, the mechanism of action, and ultimately the primary prescribers; all of these differ between ZYNRELEF and liposomal bupivacaine; they are not the same drug. One is a combo; one is a single agent. The dose differs: up to 400 milligrams of bupivacaine for ZYNRELEF, 266 for liposomal bupivacaine. ZYNRELEF is extended release, liposomal is not. Administration route is installation for ZYNRELEF, injection for liposomal bupivacaine. Also the site of action, be it local or regional. And then, perhaps most crucially, who prescribes it, so to speak? For ZYNRELEF, it's the surgeon carrying out the installation process, and largely with liposomal today, it's mostly the anesthesiologist performing regional blockades with it. So there are huge differences overall when you ask whether it's genuinely a comparator once you look at those fundamentals. And then finally, the last item I brought up concerns clinical efficacy, correct? Across numerous studies — and even in real-world settings, including direct comparisons with liposomal — ZYNRELEF has demonstrated superiority to the standard of care for 72 hours when it comes to lowering pain, reducing severe pain, and cutting opioid use; so for our institutions, that makes those choices pretty straightforward.
Carl Byrnes
analystExcellent. Thank you. That's quite useful; shifting to another subject, what kinds of chances are you noticing when it comes to possible complementary tuck-in acquisitions? And what kind of schedule should we anticipate regarding some activity in that area? Thanks.
Craig Collard
executiveCarl, I appreciate that excellent question. Once more, we truly attempted to make clear, both during this call and earlier ones, that we are really getting a handle on the business and running it. I believe we've demonstrated that we've more or less accomplished that through cutting expenses and similar measures. And at this point it concerns expanding product and the partnership with CrossLink along with some of those items; yet truly, the following stage is what more can we pursue from an M&A perspective? And once more, this management team has worked together previously, we've carried out these things. And we're bringing in. This is going to be announced during the coming few weeks. We're bringing in a business development person to lead that effort; and once more, we're going to become much more active, so to speak, in that space, examining possibilities and attempting to bring in complementary kinds of assets and/or companies that would be accretive to what we're doing. And we're going to be quite active here within a very brief period. If there are no additional questions, we simply want to thank everyone for joining the call today, and we look forward to next quarter's call.
Operator
operatorThat will conclude today's call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.